Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Press Release Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19April 28, 2021
Press Release Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™April 12, 2021
Press Release Cardiol Therapeutics Announces Filing of 2020 Year-end Financial Statements and MD&AApril 1, 2021
Press Release Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical OfficerMarch 30, 2021
Press Release Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and OptionsMarch 2, 2021
Press Release Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19January 21, 2021
Press Release Cardiol Therapeutics to Participate in Upcoming Virtual Investor ConferencesJanuary 7, 2021
Press Release Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™December 22, 2020
Press Release Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company’s Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19December 15, 2020
View more

2023 Cardiol Therapeutics. All right reserved.